Skip to main content
. 2022 Sep 21;36(11):2690–2704. doi: 10.1038/s41375-022-01697-9

Table 1.

clinical characteristics of AML patient samples tested for in vitro expansion from Supplementary Fig. S1A.

Sample ID Sex Age at AML Dx De novo vs. Secondary Type of samples Sample material FAB WBC at AML Dx BM blast count at AML dx MRC cytogenetics class at AML Dx Initial Tx NPM1 at dx FLT3 ITD at Dx FLT3 TKD at Dx
646 F 83.7 De novo Diagnosis PB M5b 299 70 Intermediate (abnormal) Supportive nd nd nd
90240 F 54.2 De novo Relapse3 Peritoneal fluid M1 3 nd Adverse Induction nd nd nd
80401 F 54 Secondary (MPN) Diagnosis PB M1 24 60 Intermediate (abnormal) Induction nd nd nd
9682 F 76.6 De novo Diagnosis PB Unclassified 34 nd nd Supportive nd nd nd
80529 F 29.4 De novo Diagnosis PB M4 21.1 60 Intermediate (normal) Induction Positive Intermediate Negative
90185 F 35.7 De novo Diagnosis PB Unclassified 46 nd Intermediate (normal) Induction Positive Intermediate Negative
80534 M 20.1 De novo Relapse1—persistent PB M5a 54 95 Intermediate (normal) Induction nd nd nd
90736 F 49.9 De novo Diagnosis PB Unclassified 41 nd nd Induction nd nd nd
90707 M 59 De novo Diagnosis PB M4 25 25 Intermediate (normal) Induction Positive Negative Negative
90784 F 61.9 De novo Diagnosis PB M5a 59 90 Intermediate (normal) Positive High Negative
858 M 55.9 Secondary (MPN) Diagnosis PB M1 33 70 Intermediate (normal) Induction Positive Negative Negative
100052 M 79.2 Secondary (MDS) Diagnosis PB M4 38 60 Adverse Supportive nd nd nd
100016 M 73.2 De novo Diagnosis PB M5a 20 80 Intermediate (normal) Induction Negative (K) Negative (K) Negative (K)
100006 F 63.3 De novo Diagnosis PB M5a 25 80 Intermediate (abnormal) Induction nd nd nd
100112 M 69.5 Secondary (MDS) Persistent disease PB nd 16 80 Intermediate (normal) Induction Negative Negative Negative
100116 F 65.3 De novo Diagnosis PB M4 46 nd nd Supportive nd nd nd
100118 M 61.8 De novo Persistent disease PB M1 204 90 Intermediate (normal) Induction Negative Intermediate Negative
100127 F 29.2 De novo Relapse1 PB Unclassified 10 nd nd Induction nd nd nd
100183 M 69.8 De novo Diagnosis PB M5a 88 85 Intermediate (normal) Induction Positive Negative Negative
100207 M 71.9 De novo Diagnosis PB M3 62 nd Favorable Induction nd nd nd
100249 F 67.1 De novo Diagnosis PB Unclassified 282 95 nd Induction Positive Intermediate Negative
100255 M 59.6 De novo Relapse1 PB M4 108 50 Intermediate (normal) Induction Positive Negative Positive
80014 M 52 Secondary (rads) Diagnosis PB M4Eo 35.9 90 Favorable Induction nd nd nd
90520 M 61.7 De novo Diagnosis PB Unclassified 103 39 Intermediate (normal) Induction Positive Negative Positive
100274 M 59.6 De novo Relapse1 PB M4 108 50 Intermediate (normal) Induction Positive Negative Positive
100286 M 50.5 De novo Diagnosis PB M1 77.2 90 Intermediate (abnormal) Induction nd nd nd
90272 F 29.2 De novo Diagnosis PB Unclassified 10 nd nd Induction nd nd nd
90517 M 61.8 De novo Persistent disease PB M1 204 90 Intermediate (normal) Induction Negative Intermediate Negative
90047 F 58.3 De novo Diagnosis PB M4 46.9 40 Intermediate (normal) Induction Positive Negative Negative
100347 F 63.3 De novo Diagnosis PB M1 89.9 90 Intermediate (normal) Induction Negative Negative Negative
100454 M 62.8 Secondary (MPN) Diagnosis PB Unclassified 27 50 Adverse Supportive nd nd nd